A South Korean life sciences company plans to open a genetic testing lab in North Austin, a move that could create up to 200 ...
New peptide research blend shows promise as a game-changer in the fitness space BURTON, MI, UNITED STATES, January 19, ...
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
The salmon-flavored treat helps with pain management.
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its ...
Before you buy stock in Gilead Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead ...
Zacks Investment Research on MSN
Exact Sciences (EXAS) reports Q4 loss, tops revenue estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.06 per share a year ago. These figures are ...
Students, young professionals, and industry leaders invited to explore emerging GIS trends and network with innovators ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
Dr. Cindi Love, Executive Director of Out for Undergrad, emphasized the significance of Valladares’ appointment: ...
The Q4 earnings report for Exact Sciences (NASDAQ: EXAS) was released on Friday, February 13, 2026 at 04:05 PM. Here's what investors need to know about the latest announcement. Exact Sciences missed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results